| Karla Jean Roth, MD | |
|
3860 Monroe Rd, De Pere, WI 54115-8399 | |
| (920) 496-4700 | |
| (920) 431-1967 |
| Full Name | Karla Jean Roth |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 32 Years |
| Location | 3860 Monroe Rd, De Pere, Wisconsin |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508890971 | NPI | - | NPPES |
| 32183200 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 37108 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unity Hospice | De pere, WI | Hospice |
| St Vincent Hospital | Green bay, WI | Hospital |
| Osf St Francis Hospital And Medical Group | Escanaba, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Vincent Hospital-hospital Sisters-third Order Of St Francis | 5799694675 | 562 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | Prevea Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306869276 PECOS PAC ID: 0042123150 Enrollment ID: O20031106000034 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | St Vincent Hospital-hospital Sisters-third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689694911 PECOS PAC ID: 5799694675 Enrollment ID: O20040126000012 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | St. Nicholas Hospital-sisters Of The Third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275799413 PECOS PAC ID: 8325931652 Enrollment ID: O20040202001172 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | St Mary's Hospital Medical Center Of Green Bay Inc-hospital Sisters |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649246877 PECOS PAC ID: 7719871268 Enrollment ID: O20040614000794 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | St Clare Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851477913 PECOS PAC ID: 0446211395 Enrollment ID: O20041023000037 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Entity Name | St Vincent Hospital-hospital Sisters-third Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285613638 PECOS PAC ID: 5799694675 Enrollment ID: O20080620000423 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Karla Jean Roth, MD 3860 Monroe Rd, De Pere, WI 54115-8399 Ph: (920) 496-4700 | Karla Jean Roth, MD 3860 Monroe Rd, De Pere, WI 54115-8399 Ph: (920) 496-4700 |
News Archive
MicroStockProfit.com announces an investment report featuring Curis Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
Tranzyme Pharma, a clinical-stage biopharmaceutical company, and Norgine B.V., a European specialty pharmaceutical company, announced today that they have entered into a licensing agreement that provides Norgine with the exclusive rights to develop and commercialize Tranzyme's novel ghrelin agonist, ulimorelin (TZP-101), in Europe, Australia, New Zealand, the Middle East, South Africa and North Africa. Ulimorelin is entering Phase 3 development for the treatment of gastrointestinal dysmotility conditions in acute care settings.
A team of investigators at the University of Kentucky has made a thought-provoking discovery about a type of cholesterol previously believed to be a "bad guy" in the development of heart disease and other conditions.
› Verified 9 days ago
Manisha Chaturvedi, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1881 Chicago St, De Pere, WI 54115 Phone: 920-403-8000 | |
Lesley J Kieffer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Lawrence Dr, De Pere, WI 54115 Phone: 920-983-3220 | |
Dr. Scott M Stillwell, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1500 Heritage Rd Ste A, De Pere, WI 54115 Phone: 920-605-3115 Fax: 920-486-6826 | |
Stephen Raymond Perry, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 3860 Monroe Rd, De Pere, WI 54115 Phone: 920-496-4700 Fax: 920-431-1967 | |
Michael J Hodulik, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1800 Lawrence Dr, De Pere, WI 54115 Phone: 920-983-3220 Fax: 920-983-3226 | |
James J Joyce, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1716 Lawrence Dr, De Pere, WI 54115 Phone: 920-605-3115 Fax: 920-486-6826 | |
Christine Ripp, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3860 Monroe Rd, De Pere, WI 54115 Phone: 920-496-4700 |